SecBot SecBot
PRESS-RELEASE ·Filed Mar 11, 2026

PHVS

Pharvaris N.V.
NEUTRAL
Impact 4/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Traders should monitor upcoming catalysts: NDA submission for deucrictibant IR capsule (H1 2026) and topline data from CHAPTER-3 (Q3 2026), which are more likely to move the stock than this validation study.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$27.43
T+0 close · Mar 11, 2026 · via day close
Latest settled
+9.88%
T+60 · $30.14
Vs SPY
−1.64%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 11 $27.43entry
  2. T+1 · 8mo ago −3.83%α −2.34% · $26.38
  3. T+5 · 8mo ago −4.59%α −2.40% · $26.17
  4. T+20 · 7mo ago −1.31%α −1.84% · $27.07
  5. T+60 · 6mo ago +9.88%α −1.64% · $30.14
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharvaris announced the publication of a real-world study validating patient-reported outcome measures (PGI and AMRA) used in clinical trials for on-demand treatment of hereditary angioedema (HAE), supporting the endpoint hierarchy in its ongoing Phase 3 RAPIDe-3 trial of deucrictibant. The findings reinforce the patient-centric design of the trial and may influence future HAE treatment assessments.

Key Facts

  • Study validates PGI and AMRA instruments as reliable tools for assessing patient experience during HAE attacks.
  • Findings support the hierarchical endpoint structure in the Phase 3 RAPIDe-3 trial of oral deucrictibant for on-demand HAE treatment.
  • End of Progression™ was identified as the first meaningful milestone, followed by symptom relief and resolution.
  • Deucrictibant has orphan drug designation in the U.S., EU, and Switzerland for bradykinin-mediated angioedema.
  • NDA submission for deucrictibant immediate-release capsule expected in first half of 2026; CHAPTER-3 topline data expected Q3 2026.

Financial Impact

No direct financial impact disclosed; supports clinical development pathway without immediate revenue or cost implications.

revenueepspipeline_value

Risk Factors

  • Regulatory uncertainty regarding approval of deucrictibant despite validated endpoints.
  • Clinical trial results may not replicate prior efficacy in larger studies.
  • Competition from existing and emerging HAE therapies could limit market adoption.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3253609

Track record

51 reports on PHVS

Performance horizon

15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
  3. Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  4. Nov 12, 20264d ago 6-K Neutral 4/10 No price data
  5. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  6. Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
  7. Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  8. Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  9. Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
  10. Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
Showing 10 of 51

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 11, 2026